LRP1B and non-small cell lung carcinoma: In a previous study, Chen et al. [30] found that significant mutations of LRP1B in melanoma and non-small-cell lung cancer were associated with their prognosis and that patients with LRP1B mutations had higher level of TMB and better immunotherapeutic efficacy.